Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOACs vs Warfarin Early After Cardiac Surgery
NCT05006287Phase 2Active, not recruiting
- Sponsor
- St. Paul's Hospital
- Start
- Oct 2022
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Atrial fibrillation (AFib), Arterial embolism (ATE) and venous thromboembolism (VTE) (2 arms), sponsored by St. Paul's Hospital. Primary endpoints: Successful recruitment rate at 3 months, Adherence rate to the anticoagulation protocol at 3 months and 1 more. Started Oct 2022; status: active, not recruiting.
02
Conditions
Atrial fibrillation (AFib)Arterial embolism (ATE)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05006287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006287.